TOP STORIES

• REGULATORY Japan Allocates 100 Billion-Plus Yen for Drug Innovation, Generic Funds: FY2025 Extra Budget
  December 1, 2025

• BUSINESS Insmed Japan to Double Sales Force with Brensocatib Launch on the Horizon
  November 28, 2025

• REGULATORY US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List
  November 27, 2025

• BUSINESS Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
  November 26, 2025

• BUSINESS Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth
  November 25, 2025

• BUSINESS Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
  November 25, 2025

• REGULATORY LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks
  November 25, 2025

• REGULATORY Japan Finalizes Economic Package Positioning Pharma as “Core Industry”
  November 25, 2025

• REGULATORY Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
  November 21, 2025

• REGULATORY Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
  November 21, 2025

• REGULATORY Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
  November 20, 2025

• REGULATORY Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
  November 20, 2025

• BUSINESS Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
  November 20, 2025

• ORGANIZATION PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
  November 19, 2025

• BUSINESS Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes
  November 18, 2025

• REGULATORY Japan Launches Pilot Expert Committee System for Patent Linkage Reviews, Aims to Reduce IP Feuds
  November 17, 2025

• COMMENTARY MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
  November 17, 2025

• REGULATORY Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
  November 17, 2025

• BUSINESS Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar
  November 17, 2025

• REGULATORY Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
  November 17, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• …
• Next ›
• 最終 »